Valeant Pharmaceuticals North America CLENZIderm M Recall

Why it was recalled

Discoloration.

Product description

CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04

Lot numbers, UPCs & expiration codes

Lot #: 15J1277, Exp. 04/2017

Where it was sold

nationwide

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-0672-2017
Classification: Class III
Status: Terminated
Recall initiated: Mar 20, 2017
FDA report date: Apr 26, 2017
Quantity: 38,767 units
Recall type: Voluntary: Firm initiated
Recalling firm: Valeant Pharmaceuticals North America LLC

Original FDA data

Every field from FDA enforcement report D-0672-2017, exactly as published.

Show all FDA fields

City: Bridgewater
State: NJ
Status: Terminated
Country: United States
Event ID: 76743
Address: 400 Somerset Corporate Blvd
Code information: Lot #: 15J1277, Exp. 04/2017
Postal code: 08807-2867
Report date: Apr 26, 2017
Product type: Drugs
Recall number: D-0672-2017
Classification: Class III
Recalling firm: Valeant Pharmaceuticals North America LLC
Product quantity: 38,767 units
Termination date: Jun 14, 2019
Reason for recall: Discoloration.
Voluntary / mandated: Voluntary: Firm initiated
Product description: CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04
Distribution pattern: nationwide
Recall initiation date: Mar 20, 2017
Initial firm notification: Letter
Center classification date: Apr 17, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0672-2017, published Apr 26, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.